tHEORetically Speaking -

Exelixis, Inc. has announced a clinical development collaboration with Merck to support the upcoming STELLAR-316 phase 3 pivotal trial. Under the agreement, Merck will supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), its subcutaneous anti-PD-1 therapy, to be evaluated in combination with Exelixis’ investigational oral kinase ...

Relay Therapeutics announced promising mid-stage clinical trial results for its drug prospect, zovegalisib, in treating vascular anomalies—a cluster of chronic conditions driven by PIK3CA gene mutations that cause abnormal blood vessel development. In a trial of 20 patients, the therapy demonstrated a 60% overall response rate across a 12-week reg...

Neptune Medical’s Triton gastrointestinal robot successfully met its primary endpoints in a breakthrough first-in-human clinical trial. The study, which involved 50 adult patients in Poland, reported a 100% cecal intubation rate, meaning the robotic system successfully guided the endoscope through the entire colon in every procedure. Crucially, th...

Eli Lilly has announced an additional $4.5 billion investment into its massive manufacturing complex in Lebanon, Indiana, bringing its total commitment to U.S. manufacturing to over $50 billion since 2020. This latest funding will bolster the “Lilly Lebanon Advanced Therapies” genetic medicine plant and the “Lilly Lebanon API” facility, which is s...

Novo Nordisk’s oral Wegovy pill has recorded a historic debut, reaching 1 million patients and generating $355 million in first-quarter sales in the United States, surpassing analyst expectations by 86%. Driven by this unprecedented uptake and improved sales performance, the Danish pharmaceutical company has raised its 2026 sales growth and operating profit outlook to ...